Recent Updates
Recently added Catalysts

MK0429

Phase 2

Post-Menopausal Osteoporosis | Small molecule | Endocrine |Merck & Company, Inc.|Last Updated: Jul 29, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment227
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00533650Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)PHASE2 COMPLETED 227Dec 1, 2000Oct 1, 2002Jul 29, 2016 -
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0429DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range50 Years — 75 Years
SexFEMALE
Healthy VolunteersNo

Inclusion Criteria: * Person is a women with osteoporosis who is unwilling or unable to take other treatments for osteoporosis Exclusion Criteria: * Person has had a previous fracture * Person has rheumatoid arthritis. Person has has certain types of cancer * Person has donated blood or has been ...

Unlock Eligibility Criteria